Tysabri and Progressive Multifocal Leukoencephalopathy: Understanding the Risks

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Awareness to Targeted Legal Concern

If you or a loved one is taking Tysabri and experiencing new neurological symptoms like confusion, weakness, or vision changes, understanding the link to progressive multifocal leukoencephalopathy (PML) is critical. The historical emphasis on balancing therapeutic benefits with adverse effects has evolved into a focused scrutiny of PML risk in patients with prior immunosuppressant exposure. This page reviews the clinical red flags, risk stratification, and current pharmacovigilance practices.

Understanding Tysabri and Its Link to PML

Tysabri (natalizumab) is a monoclonal antibody used to treat multiple sclerosis and Crohn's disease. Its use carries a well-documented risk of Progressive Multifocal Leukoencephalopathy (PML), a severe opportunistic viral infection of the brain caused by the JC virus. PML typically occurs in immunocompromised individuals and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The clinical presentation of PML is variable, but common symptoms include progressive neurological deficits such as weakness, cognitive decline, visual disturbances, and coordination problems. Diagnosis relies on brain imaging, typically MRI showing demyelinating lesions, and detection of JC virus DNA in cerebrospinal fluid. A retrospective national cohort study of 456 PML cases observed between 1987 and 2024 described changing clinical and laboratory characteristics, highlighting the importance of early recognition in affected populations (https://pubmed.ncbi.nlm.nih.gov/40922664/). The pharmacological mechanism linking Tysabri to PML involves its action as an alpha-4 integrin antagonist. Tysabri blocks the adhesion of immune cells to endothelial cells, preventing their migration into the central nervous system. This immunosuppressive effect reduces immune surveillance, allowing latent JC virus to reactivate and cause PML.

FDA Warnings and Risk Factors for PML

The FDA-approved label for Tysabri includes a boxed warning stating that the drug increases the risk of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three specific risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond 2 years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). In clinical trials, PML occurred in three patients: two among 1869 multiple sclerosis patients treated for a median of 120 weeks (both had also received interferon beta-1a), and one among 1043 Crohn's disease patients after eight doses (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The adequacy of warnings regarding Tysabri and PML is a critical risk consideration. The boxed warning explicitly states that Tysabri increases PML risk and that healthcare professionals should monitor patients for any new signs or symptoms suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The label also mandates that Tysabri dosing be withheld immediately at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Furthermore, Tysabri is only available through a restricted distribution program called the TOUCH Prescribing Program, designed to manage the risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these warnings, questions may arise about whether patients and healthcare providers fully understand the magnitude of risk, particularly regarding the interplay of risk factors and the need for vigilant monitoring.

Legal Considerations for PML Patients in New York

For affected patients, attorney-related considerations are important. Individuals who develop PML after Tysabri treatment may seek legal counsel to explore whether adequate warnings were provided and whether the benefits of treatment were properly weighed against the risks. The timeline between exposure and documented harm is variable. In clinical trials, PML occurred after a median treatment duration of 120 weeks in multiple sclerosis patients and after eight doses in a Crohn's disease patient (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, PML can occur at any time during treatment, and risk increases with longer exposure. The presence of anti-JCV antibodies is a key predictor, and testing for these antibodies is recommended before and during treatment. Patients who develop PML often face severe disability or death, and legal action may focus on whether the manufacturer provided sufficient information about risk stratification and monitoring protocols. In summary, Tysabri is associated with a significant risk of PML, a devastating brain infection. The drug's label includes a boxed warning and identifies specific risk factors, but the adequacy of these warnings in clinical practice remains a concern. Patients who suffer PML may have legal recourse, particularly if they were not adequately informed about the risks or if monitoring was insufficient. The timeline from exposure to harm can span months to years, underscoring the need for ongoing vigilance.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.

Frequently Asked Questions

What is Tysabri and how does it cause PML?

Tysabri (natalizumab) is a monoclonal antibody used to treat multiple sclerosis and Crohn's disease. It increases the risk of Progressive Multifocal Leukoencephalopathy (PML), a severe brain infection caused by the JC virus. The drug works by blocking immune cell migration into the central nervous system, which reduces immune surveillance and allows latent JC virus to reactivate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What are the risk factors for developing PML while on Tysabri?

Three key risk factors are identified: presence of anti-JCV antibodies, longer treatment duration (especially beyond 2 years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Can I file a lawsuit if I developed PML after taking Tysabri?

Yes, patients who develop PML after Tysabri treatment may have legal recourse, particularly if they were not adequately informed about the risks or if monitoring was insufficient. An attorney can help evaluate whether the manufacturer provided adequate warnings and whether the benefits were properly weighed against the risks.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.